Annexon (ANNX) reported "rapid recovery and durable benefit" for patients in the phase 3 trial of tanruprubart, a potential targeted therapy for Guillain-Barre Syndrome,
The trial showed a 2.4-fold higher likelihood of improvement at week eight versus placebo in 241 patients, the company said Tuesday in a statement, with the results presented at the American Academy of Neurology annual meeting in San Diego.
Key findings showed that tanruprubart led to a 14-fold improvement in mobility at week one and twice as many patients had no limitations by week 26, the company said.
Shares of the company rose 3.3% in recent after-hours trading, paring earlier gains.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。